script.reportAU
Register
← The record

Alogliptin

Recommended EndocrinologyAuthority RequiredLater-line line

Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

1
Submissions
2013–13
On the record
—
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Jul 2013 Recommended Type 2 Diabetes

Access path

1 submission · public record
  1. Jul 2013
    Recommended · restricted

    vs sitagliptin

  2. PBS listing · Authority Required
RecommendedDeferredNot recommended

Cost-effectiveness

Cost-minimisation analysis performed; no ICER calculated as the analysis was based on non-inferiority claim with equivalent effectiveness to sitagliptin.

The submission presented a cost-minimisation analysis of alogliptin dual therapy compared to sitagliptin dual therapy. PSD · 2013

Decision context

PopulationAdults with type 2 diabetes in combination with metformin or a sulfonylurea, whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor, a thiazolidinedione or a glucagon-like peptide-1.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Jul 2013 Recommended · restricted sitagliptin — RCT · HbA1c reduction

Similar precedents

By decision profile
Alogliptin With Metformin93%Saxagliptin79%Linagliptin77%Saxagliptin With Metformin77%Linagliptin With Metformin Hydrochloride76%Metformin And Sitagliptin77%Metformin And Saxagliptin76%Sitagliptin Phosphate75%

Regulatory · TGA

Label narrower than PBS population — PBAC restricted to HbA1c >7% despite prior monotherapy and later-line use; TGA label has no glycemic or treatment-history criteria.